It is not yet clear what determines if CD8+ T cells or CD4+ T cells or both will mediate antitumor immunity: whether this depends on Fas/Fas ligand interactions (37, 65, 66), MHC class I/II expression, the tumor type, the type of treatment, or other mechanisms. Here, CD8A is linked to neoplasm.